Travelzoo (TZOO) Reaches $15.66 After 6.00% Down Move; Adaptimmune Therapeutics plc (ADAP) Had 5 Analysts Last Week

May 21, 2018 - By Hazel Jackson

Travelzoo (NASDAQ:TZOO) Logo

The stock of Travelzoo (NASDAQ:TZOO) is a huge mover today! The stock decreased 2.45% or $0.39 during the last trading session, reaching $15.66. About 63,358 shares traded. Travelzoo (NASDAQ:TZOO) has declined 23.28% since May 21, 2017 and is downtrending. It has underperformed by 34.83% the S&P500.The move comes after 9 months negative chart setup for the $195.11M company. It was reported on May, 21 by We have $14.72 PT which if reached, will make NASDAQ:TZOO worth $11.71 million less.

Among 7 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Adaptimmune Therapeutics PLC had 8 analyst reports since February 25, 2016 according to SRatingsIntel. Leerink Swann initiated Adaptimmune Therapeutics plc (NASDAQ:ADAP) on Friday, March 16 with “Buy” rating. The rating was maintained by SunTrust on Saturday, November 11 with “Buy”. The rating was downgraded by Bank of America to “Underperform” on Monday, October 24. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) has “Buy” rating given on Thursday, February 25 by Citigroup. The firm earned “Buy” rating on Friday, March 16 by Cowen & Co. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Buy” rating by Cowen & Co on Tuesday, June 6. See Adaptimmune Therapeutics plc (NASDAQ:ADAP) latest ratings:

16/03/2018 Broker: Cowen & Co Rating: Buy Maintain
16/03/2018 Broker: Raymond James Rating: Buy New Target: $20.0
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $15.0 Initiate

Investors sentiment decreased to 0.65 in Q4 2017. Its down 0.18, from 0.83 in 2017Q3. It dropped, as 4 investors sold Travelzoo shares while 16 reduced holdings. 2 funds opened positions while 11 raised stakes. 2.72 million shares or 5.09% less from 2.87 million shares in 2017Q3 were reported. Peak6 Invs Limited Partnership has invested 0% in Travelzoo (NASDAQ:TZOO). Geode Capital Mngmt Llc holds 44,847 shares or 0% of its portfolio. 256,649 were reported by Blackrock Inc. Dimensional Fund Advisors L P has invested 0% in Travelzoo (NASDAQ:TZOO). Savings Bank Of America De has invested 0% in Travelzoo (NASDAQ:TZOO). Vanguard Grp Inc holds 233,578 shares or 0% of its portfolio. Renaissance Tech Lc has 518,700 shares. California Pub Employees Retirement Systems holds 0% of its portfolio in Travelzoo (NASDAQ:TZOO) for 100,100 shares. Moreover, Menta Ltd Liability Corp has 0.14% invested in Travelzoo (NASDAQ:TZOO) for 110,026 shares. Manufacturers Life Insurance The accumulated 114 shares. Barclays Plc holds 410 shares or 0% of its portfolio. Macquarie Group Limited accumulated 20,142 shares or 0% of the stock. Ajo L P holds 0% or 16,118 shares. Tower Research Capital Limited Liability Corp (Trc) reported 2,567 shares. Morgan Stanley accumulated 600 shares.

Since February 13, 2018, it had 0 insider buys, and 3 insider sales for $1.98 million activity. AZZURRO CAPITAL INC had sold 42,196 shares worth $298,280.

Travelzoo Inc., together with its subsidiaries, provides travel, entertainment, and local deals from travel and entertainment companies, and local businesses in the Asia Pacific, Europe, and North America. The company has market cap of $195.11 million. The companyÂ’s publications and products include Travelzoo Websites, such as,,,,,,,,,,, and others; Travelzoo iPhone and Android applications; Travelzoo Top 20 e-mail newsletter; and Newsflash, e-mail alert services. It has a 62.88 P/E ratio. It also operates SuperSearch, a pay-per-click travel search tool; the Travelzoo Network, a network of third-party Websites that list travel deals published by the company;, a travel search engine that enables users to find the prices on flights from various airlines and online travel agencies; and Local Deals and Getaway services, which allow its subscribers to purchase vouchers for deals from local businesses, including spas, hotels, and restaurants through the Travelzoo Website.

More recent Travelzoo (NASDAQ:TZOO) news were published by: which released: “Travelzoo Explodes Higher, And With Good Reason” on May 02, 2018. Also published the news titled: “Travelzoo Inc 2018 Q1 – Results – Earnings Call Slides” on April 25, 2018.‘s news article titled: “Mid-Day Market Update: Travelzoo Rises Following Q1 Results; HFF Shares Tumble” with publication date: April 25, 2018 was also an interesting one.

More notable recent Adaptimmune Therapeutics plc (NASDAQ:ADAP) news were published by: which released: “Adaptimmune Reports First Quarter 2018 Financial Results and Business Update” on May 09, 2018, also with their article: “Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American …” published on May 16, 2018, published: “Adaptimmune Therapeutics (ADAP) Data with NY-ESO and MAGE-A10 Study Update to be Presented at ASCO” on May 16, 2018. More interesting news about Adaptimmune Therapeutics plc (NASDAQ:ADAP) were released by: and their article: “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” published on May 16, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” with publication date: May 09, 2018.

The stock increased 1.15% or $0.14 during the last trading session, reaching $12.29. About 193,815 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has risen 144.20% since May 21, 2017 and is uptrending. It has outperformed by 132.65% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.16 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Travelzoo (NASDAQ:TZOO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: